Allelic loss or reduced expression of RB occurs in 25% to 50% of human prostate cancer [32–34], and PTEN deletion and/or mutations were detected in 30% of primary prostate cancer and 63% of metastatic prostate cancer [35, 36]. This evidence concerns the gene PTEN and prostate carcinoma.